VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

CVD 909
Vaccine Information
  • Vaccine Name: CVD 909
  • Target Pathogen: Salmonella spp.
  • Target Disease: Salmonellosis
  • Vaccine Ontology ID: VO_0004138
  • Type: Live, attenuated vaccine
  • Status: Licensed
  • HtrA gene engineering:
    • Type: Recombinant protein preparation
    • Description: CVD 909 was constructed by replacing the native promoter of tviA with the strong constitutive promoter Ptac (Wang et al., 2000).
    • Detailed Gene Information: Click Here.
  • Preparation: S. Typhi CVD 909 was constructed to express the Vi-antigen. This involved a deletion in the promoter region of tviA and an insertion of the sacB-neo cassette, introduced into the chromosome of CVD 908-htrA by homologous recombination. The replacement of the sacB-neo cassette allowed the replacement of the promoter region with the Ptac promoter in a second homologous recombination event (Wang et al., 2000).
Host Response

Human Response

  • Vaccination Protocol: 24 volunteers received a single oral dose of CVD 909 of 106–109 cfu, and 8 adults received 2 doses of 6 × 109 cfu per dose with buffer 14 days apart (Tacket and Levine, 2007).
  • Immune Response: All volunteers tested developed IgA anti-LPS ASCs. However, only 1 of the volunteers who ingested a single dose and only 1 of the 8 volunteers who ingested 2 doses developed serum IgG anti-Vi .However, IgA anti-Vi ASC responses were detected in a majority of volunteers who received 108–109 cfu of CVD 909. These Vi-specific ASC responses provided evidence that the Vi antigen was expressed and immunologically processed, even if serum antibody responses were realitvely small (Tacket and Levine, 2007).
  • Side Effects: Not noted.

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Three groups of 6-week-old BALB/c mice were immunized once intranasally with 1010 CFU of either serovar Typhi strain CVD 908-htrA or CVD 909 or PBS (control) (Wang et al., 2000).
  • Immune Response: The mean titer of IgG anti-Vi was much higher in the mice that received CVD 909. However, GMTs of O antibody after immunization were quite similar in the two groups (CVD 909 and CDV 908-htrA) (Wang et al., 2000).
  • Side Effects: Not noted.
  • Challenge Protocol: Mice were challenged with wild-type serovar Typhi strain Ty2 thirty days after primary immunization (Wang et al., 2000).
  • Efficacy: A single mucosal dose of CVD 909 conferred significantly greater protection than CVD 908-htrA (Wang et al., 2000).
References
Tacket and Levine, 2007: Tacket CO, Levine MM. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007; 45 Suppl 1; S20-23. [PubMed: 17582563].
Wang et al., 2000: Wang JY, Noriega FR, Galen JE, Barry E, Levine MM. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909. Infection and immunity. 2000; 68(8); 4647-4652. [PubMed: 10899868].